{"schema_version":"secwatch.filing_event.v1","accession":"0001398733-25-000012","form_type":"8-K","ticker":"AQST","cik":"0001398733","company_name":"Aquestive Therapeutics, Inc.","filed_at":"2025-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.889730+00:00","generated_at":"2026-05-17T15:19:10.841927+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Aquestive Q2 net loss $13.5M; FDA accepts Anaphylm NDA, PDUFA Jan 31, 2026","bullets":["Total revenue $10.0M, down 50% YoY; excluding one-time deferred revenue, up 3% to $10.0M.","Net loss $13.5M ($0.14/sh) vs $2.7M loss ($0.03) in Q2 2024; adjusted EBITDA loss $9.3M.","Cash $60.5M at June 30; FY2025 guidance: revenue $44-50M, adjusted EBITDA loss $47-51M.","FDA accepted Anaphylm NDA; PDUFA date Jan 31, 2026; Q1 2026 launch planned if approved.","Anaphylm global expansion to Canada and EU; AQST-108 IND for alopecia areata expected Q4 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001398733-25-000012","json":"https://secwatch.observer/filing/0001398733-25-000012.json","markdown":"https://secwatch.observer/filing/0001398733-25-000012.md","text":"https://secwatch.observer/filing/0001398733-25-000012.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1398733/000139873325000012/0001398733-25-000012-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1398733/000139873325000012/aqst-20250811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T15:19:10.841927+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}